Director of Surgical Pathology from 1999-2007. Currently Director of Anatomic Pathology. Through recruitment and collaborations, Dr. Boyce has increased the depth and breadth of both clinical and research expertise in the department. He is a general diagnostic surgical pathologist, who has had a sub-specialty interest in the pathology of metabolic bone disease since 1976 when he began to collaborate with Dr. Iain Boyle and his group in Glasgow and with Dr. Pierre Meunier in Lyons, France after training in 1977.

Qualifications

M.B., Ch.B., University of Glasgow 1972
Fellow, Royal College of Pathologists 1991
General Medicine Resident, Western Infirmary, Glasgow 1972-73
General Surgery Resident, Royal Infirmary, Glasgow 1973
Pathology Resident, Royal Infirmary, Glasgow 1973-76
Jean Mackintosh Research Fellow, University of Lyon, France 1977

Research Overview

The major focus of research in my lab is study of the regulation of the formation, activation and survival of osteoclasts, the cells that resorb bone. In recent years, many genes have been identified as regulators of these aspects of osteoclast function, and our studies presently are focussed on the roles of NF-kappaB and src tyrosine kinase in osteoclasts. My colleague, Dr. Lianping Xing, and I, along with members of the Center for Musculoskeletal Research at the University, are studying the roles of these gene products in the increased bone resorption and decreased bone formation that characterize a number of bone diseases, including postmenopausal osteoporosis, inflammatory joint disease, metastatic bone disease and loosening of joint prostheses. We are also studying the effects of a number of potential drug development compounds developed by ARIAD Pharmaceuticals on bone resorption and bone formation, using a number of models of human bone diseases. NF-kappaB also appears to regulate chondrocyte differentiation, and we are studying its role in endochondral ossification. We acknowledge funding from the National Institutes of Health to support our studies: AR-43510-07, AR 49503-01, AR-48697-01 (Dr. Xing).

Publications

Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis. Res. Ther. 2007;9 Suppl 1:S1.

Boyce BF, Xing L. Osteoclasts, no longer osteoblast slaves. Nat. Med. 2006 12:1356-1358.

Boyce BF, Xing L, Yao Z, Yamashita T, Wang Y, Shakespeare W, Metcalf C, Sundaramoorthi, Dalgarno D, Iuliucci J, Sawyer T. Src inhibitors in metastatic bone disease. Clin. Cancer Res. 2006; 12:6291s-6295s

Morello R, Bertin T, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, Bachinger, HP, Weis MA, Fernandes R, Eyre DR, Yao Z, Boyce BF, Lee B. CRTAP is required for collagen 3-prolyl-hydroxylation and loss of its function causes recessive Osteogenesis Imperfecta. Cell 2006; 127:291-304.

Schwarz EM, Looney J, Drissi MH, O’Keefe RJ, Boyce BF, Xing L, Ritchlin CT. Autoimmunity and bone. Proc. N.Y. Acad. Sci. 2006; 1068: pp 275-283.

Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol. 2006; 18:427-32.

Boyce BF, Xing L, Yao Z, Yamashita T, Wang Y, Shakespeare W, Metcalf C, Sundaramoorthi, Dalgarno D, Iuliucci J, Sawyer T. Anti-catabolic therapeutic targets in bone disease. Proc. N.Y. Acad. Sci. 2006; 1068: pp 447-457.

Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, Boyce BF, Xing L. Tumor Necrosis Factor-{alpha} Increases Circulating Osteoclast Precursor Numbers by Promoting Their Proliferation and Differentiation in the Bone Marrow through Up-regulation of c-Fms Expression. J Biol Chem. 2006 Apr 28;281(17):11846-55. Epub 2006 Feb 6.

Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, Boyce BF, Xing L. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem. 2006 Feb 17;281(7):4326-33. Epub 2005 Dec 22.

Boyce BF, Xing L, Chen D. Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. Cell Metab. 2005 Dec;2(6):344-5. No abstract available.

Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev. 2005 Dec;208:19-29. Review.

Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'Keefe RJ, Xing L. TNF-alpha and pathologic bone resorption. Keio J Med. 2005 Sep;54(3):127-31. Review.

Zhang Q, Badell IR, Schwarz EM, Boulukos KE, Yao Z, Boyce BF, Xing L. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum. 2005 Sep;52(9):2708-18.

Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab. 2005;23 Suppl:11-5. Review.

Carmouche JJ, Puzas JE, Zhang X, Tiyapatanaputi P, Cory-Slechta DA, Gelein R, Zuscik M, Rosier RN, Boyce BF, O'Keefe RJ, Schwarz EM. Lead exposure inhibits fracture healing and is associated with increased chondrogenesis, delay in cartilage mineralization, and a decrease in osteoprogenitor frequency. Environ Health Perspect. 2005 Jun;113(6):749-55.

Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J, Zhang X, Rubery PT, Rabinowitz J, Samulski RJ, Nakamura T, Soballe K, O'Keefe RJ, Boyce BF, Schwarz EM. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy . Nat Med. 2005 Mar;11(3):291-7. Epub 2005 Feb 13.

Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 2005 Mar 18;328(3):709-20. Review.

Kapur RP, Yao Z, Iida MH, Clarke CM, Doggett B, Xing L, Boyce BF.
Malignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank. J Bone Miner Res. 2004 Oct;19(10):1689-1697. PubMed Publication List .

Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res. 2004 Feb;19(2):207-13. PubMed Publication List.

Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 2004 Jan;50(1):265-76. PubMed Publication List.

Feng JQ, Xing L, Zhang JH, Zhao M, Horn D, Chan J, Boyce BF, Harris SE, Mundy GR, Chen D. NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem. 2003 Aug 1;278(31):29130-5. Epub 2003 May 20. PubMed Publication List.

Boyce BF, Xing L, Shakespeare W, Wang Y, Dalgarno D, Iuliucci J, Sawyer T. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl. 2003 Jun;(85):2-5. PubMed Publication List.

Boyce BF. Bad bones, grey hair, one mutation. Nat Med. 2003 Apr;9(4):395-6. PubMed Publication List.

Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, Huang KE, Lin H, Yeh SD, Altuwaijri S, Zhou X, Xing L, Boyce BF, Hung MC, Zhang S, Gan L, Chang C, Hung MC. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13498-503. PubMed Publication List.

Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res. 2002 Jul;17(7):1200-10. PubMed Publication List.

Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res. 2002 Feb;17(2):192-9. PubMed Publication List.

Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U, Boyce BF. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res. 2003 Feb;18(2):260-9. PubMed Publication List.

Boyce BF, Xing L, Jilka RL, Bellido T, Weinstein RS, Parfitt AM, Manolagas SC. Apoptosis in bone cells. Principles Bone Biol. 2002, 1:151-168.

Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Varmus HE, Schwartzberg PL. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001 Jan 15;15(2):241-53. PubMed Publication List.

 

Helpful Links

• Pathology Department Faculty List
• Areas of Excellence - Anatomic Pathology
• Areas of Excellence - Clinical Pathology
• Pathology Ph.D. Program Faculty

Pathology & Laboratory Medicine Sites

Pathology and Laboratory Medicine URMC Clinical Laboratories URMC Central Laboratory Research and Academics Residency Program Graduate Studies